Back to Newsroom

Puma Biotechnology, Inc. Updated five-year ExteNet analysis in line with prior presentation

First impression ESMO abstracts: iDFS benefit of Nerlynx maintained in updated five-year analysis of ExteNet. The abstract for the upcoming ESMO presentation of updated five-year analysis of the Phase III ExteNet trial of Nerlynx (neratinib) was released online this evening (full abstract on page 2). Notably, iDFS results indicate that the benefit of Nerlynx observed at two years is maintained out to five years for the ITT population and is more pronounced in the subgroup of hormone receptor positive patients (2.5% benefit vs. pbo for ITT; 4.4% benefit for HR+).